Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication

NCT06843512 | Recruiting FDA Drug

• 1 other identifier: STUDY00026642
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.

Conditions

Weight Loss; Food Selection

Keywords

GLP-1; Weight Loss; Virtual Reality; Food behavior

Outcome Measures

Primary Outcomes (4)

• Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 Months

  Baseline and 3 months

• Change from Baseline in Total Calories of Food Selected in the VR Buffet at 3 Months

  Baseline and 3 months

• Change from Baseline in Energy Density of Food Selected in the VR Buffet at 3 Months

  Baseline and 3 months

• Change from Baseline in Variety of Food Selected in the VR Buffet at 3 Months

  Baseline and 3 months

Secondary Outcomes (6)

• Change in Baseline Weight Watchers Food Noise Score at 3 Months

  Baseline and 3 months

• Change in Baseline 9-question External Food Cue Responsiveness Questionnaire Score at 3 Months

  Baseline and 3 months

• Change in Baseline Adult Eating Behavior Score at 3 Months

  Baseline and 3 months

• Change in Baseline Three-Factor Eating Questionnaire Score at 3 Months

  Baseline and 3 months

• Change in Baseline General Food Craving-Trait Scale Score at 3 Months

  Baseline and 3 months

Other Outcomes (1)

• Change in Baseline BMI at 3 Months

  Baseline and 3 months

Interventions

GLP-1 Medication Initiation OTHER

One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be identified from a list of medical patients prescribed GLP-1 medication by their physicians (located in offices near State College or Hershey, PA) and who volunteered to be contacted regarding studies they are eligible for.

You may qualify if:

• Adults (18+) with overweight or obesity (BMI \>25 kg/m2)
• Not currently taking an incretin-based medication at baseline
• Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
• Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
• Fluent in English

You may not qualify if:

• Adults (18+) without overweight or obesity
• \<18 years of age at time of testing
• Adults not taking a GLP-1 Medication
• Adults taking a compound GLP-1
• Adults on GLP-1 medication for longer than 2 weeks at baseline
• Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
• Not fluent in English

Sponsors & Collaborators

• Penn State University: lead

Study Sites (1)

Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University

State College, Pennsylvania, 16802, United States

RECRUITING

MeSH Terms

Conditions

Weight Loss; Food Preferences

Condition Hierarchy (Ancestors)

Body Weight Changes; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Feeding Behavior; Behavior

Study Officials

• Travis Masterson

  The Pennsylvania State University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Christina M Blackmon

CONTACT

425-499-8049; cmb8633@psu.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor and Director of the Health, Ingestive Behavior, and Technology Lab

Study Record Dates

• First Submitted: February 20, 2025
• First Posted: February 25, 2025
• Study Start: July 15, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: September 10, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)